Cystamine ameliorates liver fibrosis induced by carbon tetrachloride via inhibition of tissue transglutaminase

Figure 1 Histologic appearance of representative livers for cystamine treatment and fibrosis control rats. A, B: Cystamine treatment ameliorated liver damage (A × 100, B × 200); C, D: Fibrosis control livers from CCl₄-treated rats showed substantial damage including inflammation, fine fibrils and degeneration of hepatocytes (C × 100, D × 200).

Figure 2 Hepatic function changes of each group. A: the level of ALT after Cystamine treatment; B: the level of TB after Cystamine treatment; C: the level of TBA after Cystamine treatment. ^bP < 0.01 vs Control; ^dP < 0.01 vs Fibrosis.

Figure 3 Difference of mRNA expression in each group. A: relative expression of tTG after Cystamine treatment; B: relative expression of a-SMA after Cystamine treatment; C: relative expression of Collagen-1 after Cystamine treatment; D: relative expression of TIMP-1 after Cystamine treatment. ^bP < 0.01 vs Control; ^dP < 0.01 vs Fibrosis.

Figure 4 Different level of tTG protein in each group. tTG relative expression after Cystamine treatment. ^bP < 0.01 vs Control; ^dP < 0.01 vs Fibrosis.

Figure 5 Different level of α-SMA protein in each group. α-SMA relative expression after Cystamine treatment. ^bP < 0.01 vs Control; ^dP < 0.01 vs Fibrosis.